TY - ADVS
T1 - TRAXAR Trial: Adding Novel Monoclonal Antibody to Axitinib in Advanced Kidney Cancer
AU - Cutter, Noelle L
N1 - By: Noelle Cutter, PhD Posted: Friday, May 7, 2021 The phase II multicenter, international TRAXAR trial, published in The Oncologist, evaluated the clinical outcomes with a novel combination for patients with advanced or metastatic renal cell carcinoma who had experienced disease progression following therapy with one or more VEGF inhibitors.
PY - 2021/5/8
Y1 - 2021/5/8
N2 - The phase II multicenter, international TRAXAR trial, published in The Oncologist, evaluated the clinical outcomes with a novel combination for patients with advanced or metastatic renal cell carcinoma who had experienced disease progression following therapy with one or more VEGF inhibitors. Toni K. Choueiri, MD, and researchers from Dana-Farber Cancer Institute, Boston, determined that the combination of the antiendoglin monoclonal antibody carotuximab with the VEGFR inhibitor axitinib did not improve progression-free survival over axitinib monotherapy
AB - The phase II multicenter, international TRAXAR trial, published in The Oncologist, evaluated the clinical outcomes with a novel combination for patients with advanced or metastatic renal cell carcinoma who had experienced disease progression following therapy with one or more VEGF inhibitors. Toni K. Choueiri, MD, and researchers from Dana-Farber Cancer Institute, Boston, determined that the combination of the antiendoglin monoclonal antibody carotuximab with the VEGFR inhibitor axitinib did not improve progression-free survival over axitinib monotherapy
UR - https://jnccn360.org/kidney/medical-literature/traxar-trial-adding-novel-monoclonal-antibody-to-axitinib-in-advanced-kidney-cancer/
M3 - Web publication/site
ER -